Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to compare the efficacy of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit (c-kit JM). The primary endpoint is Progression Free Survival (PFS).
Inclusion criteria
- Patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit